In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice

Drug Metabolism and Disposition

Volumn 34, Issue 10, 2006, Pages 1697-1702

  Sugamori, K S ^a   Brenneman, D ^a   Grant, D M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 2 FLUORENYLAMINE; 4 BIPHENYLAMINE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; DRUG METABOLIZING ENZYME;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN METABOLISM; TISSUE SPECIFICITY; TOXICOKINETICS;

AMINES; AMINOBIPHENYL COMPOUNDS; ANIMALS; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORENES; HUMANS; IMIDAZOLES; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT;

ANIMALIA;

EID: 33748886474     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010819     Document Type: Article

References (42)

1. Airoldi L, Orsi F, Magagnotti C, Coda R, Randone D, Casetta G, Peluso M, Hautefeuille A, Malaveille C, and Vineis P (2002) Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 23:861-866.
2. Buonarati MH, Roper M, Morris CJ, Happe JA, Knize MG, and Felton JS (1992) Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice. Carcinogenesis 13:621-627.
3. Butcher NJ, Boukouvala S, Sim E, and Minchin RF (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30-42.
4. Chen T, Mittelstaedt RA, Beland FA, Heflich RH, Moore MM, and Parsons BL (2005) 4-Aminobiphenyl induces liver DNA adducts in both neonatal and adult mice but induces liver mutations only in neonatal mice. Int J Cancer 117:182-187.
5. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, and Gonzalez FJ (2005) Differential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18:1471-1478.
6. Cornish VA, Pinter K, Boukouvala S, Johnson N, Labrousse C, Payton M, Priddle H, Smith AJ, and Sim E (2003) Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J 3:169-177.
7. Faraglia B, Chen SY, Gammon MD, Zhang Y, Teitelbaum SL, Neugut AI, Ahsan H, Garbowski GC, Hibshoosh H, Lin D, et al. (2003) Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 24:719-725.
8. Feng Z, Hu W, Rom WN, Beland FA, and Tang MS (2002) 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis 23:1721-1727.
9. Flammang TJ, Couch LH, Levy GN, Weber WW, and Wise CK (1992) DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl. Carcinogenesis 13:1887-1891.
10. Fletcher K, Tinwell H, and Ashby J (1998) Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of MutaMouse transgenic mice. Mutat Res 400(1-2):245-250.
11. Fretland AJ, Devanaboyina US, Doll MA, Zhao S, Xiao GH, and Hein DW (2003) Metabolic activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine in Syrian hamsters congenic at the N-acetyltransferase 2 (NAT2) locus. Toxicol Sci 74:253-259.
12. Fretland AJ, Doll MA, Gray K, Feng Y, and Hein DW (1997) Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol Appl Pharmacol 142:360-366.
13. Glowinski IB and Weber WW (1982) Biochemical characterization of genetically variant aromatic amine N-acetyltransferases in A/J and C57BL/6J mice. J Biol Chem 257:1431-1437.
14. Gonzalez FJ (2003) Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 35:319-335.
15. Grant DM, Goodfellow GH, Sugamori K, and Durette K (2000) Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 61:204-211.
16. Grant DM, Josephy PD, Lord HL, and Morrison LD (1992) Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res 52:3961-3964.
17. Heflich RH and Neft RE (1994) Genetic toxicity of 2-acetylaminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. Mutat Res 318:73-114.
18. Hein D (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507(C):65-77.
19. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42.
20. Hoivik DJ, Manautou JE, Tveit A, Hart SG, Khairallah EA, and Cohen SD (1995) Gender-related differences in susceptibility to acetaminophen-induced protein arylation and nephrotoxicity in the CD-1 mouse. Toxicol Appl Pharmacol 130:257-271.
21. Kelly SL and Sim E (1994) Arylamine N-acetyltransferase in BALB/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem J 302(Pt 2):347-353.
22. Kim D and Guengerich FP (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27-49.
23. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, and Gonzalez FJ (1999) CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 20:1825-1830.
24. Kimura S, Kawabe M, Yu A, Morishima H, Fernandez-Salguero P, Hammons GJ, Ward JM, Kadlubar FF, and Gonzalez FJ (2003) Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis 24:583-587.
25. Lai CC, Miller EC, Miller JA, and Liem A (1987) Initiation of hepatocarcinogenesis in infant male B6C3F1 mice by N-hydroxy-2-aminofluorene or N-hydroxy-2-acetylaminofluorene depends primarily on metabolism to N-sulfooxy-2-aminofluorene and formation of DNA-(deoxyguanosin-8-yl)-2- aminofluorene adducts. Carcinogenesis 8:471-478.
26. Levy GN and Weber WW (1989) 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. Carcinogenesis 10:705-709.
27. Levy GN and Weber WW (1992) 2-Aminofluorene-DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. Carcinogenesis 13:159-164.
28. McQueen CA, Chau B, Erickson RP, Tjalkens RB, and Philbert MA (2003) The effects of genetic variation in N-acetyltransferases on 4-aminobiphenyl genotoxicity in mouse liver. Chem Biol Interact 146:51-60.
29. Miller JA (1994) Sulfonation in chemical carcinogenesis - history and present status. Chem Biol Interact 92(1-3):329-341.
30. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, and Kadlubar FF (1992) N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 185:839-8442.
31. Oda Y (2004) Analysis of the involvement of human N-acetyltransferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system. Mutat Res 554(1-2):399-406.
32. Poirier MC, Fullerton NF, Smith BA, and Beland FA (1995) DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Carcinogenesis 16:2917-2921.
33. Schieferstein GJ, Littlefield NA, Gaylor DW, Sheldon WG, and Burger GT (1985) Carcinogenesis of 4-aminobiphenyl in BALB/cStCrlfC3Hf/Nctr mice. Eur J Cancer Clin Oncol 21:865-873.
34. Schmalix WA, Maser H, Kiefer F, Reen R, Wiebel FJ, Gonzalez F, Seidel A, Glatt H, Greim H, and Doehmer J (1993) Stable expression of human cytochrome P450 1A1 cDNA in V79 Chinese hamster cells and metabolic activation of benzo[a]pyrene. Eur J Pharmacol 248:251-261.
35. Shertzer HG, Dalton TP, Talaska G, and Nebert DW (2002) Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol Appl Pharmacol 181:32-37.
36. Smolen TN, Brewer JA, and Weber WW (1993) Testosterone modulation of N-acetylation in mouse kidney. J Pharmacol Exp Ther 264:854-858.
37. Stabbert R, Schafer KH, Biefel C, and Rustemeier K (2003) Analysis of aromatic amines in cigarette smoke. Rapid Commun Mass Spectrom 17:2125-2132.
38. Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 64:170-179.
39. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, and Nebert DW (2003) 4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J Natl Cancer Inst 95:1227-1237.
40. Turesky RJ, Freeman JP, Holland RD, Nestorick DM, Miller DW, Ratnasinghe DL, and Kadlubar FF (2003) Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol 16:1162-1173.
41. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, and Nebert DW (2004) Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65:1225-1237.
42. Weisburger J (2002) Comments on the history and importance of aromatic and heterocyclic amines in public health. Mutat Res 506-507(C):9-20.